Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

Among 455,306 UK Biobank participants, 37 carried one copy of the APOE Christchurch variant (allele frequency 0.004%). None of the carriers, aged 57 to 82, had developed Alzheimer's or mild cognitive impairment, and carriers had significantly lower apolipoprotein B levels than matched non-carriers, but the sample was too small to test dementia risk directly.

What this study adds

Evidence grade: Early

This is a follow-up (cohort) study of 455,306 participants. Among 455,306 UK Biobank participants, 37 carried one copy of the APOE Christchurch variant and none had developed Alzheimer's or mild cognitive impairment by the data freeze. The sample was too small to directly test dementia risk, so this cannot establish that the variant protects against Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

He, K. Y., Khramtsova, E. A., Cabrera-Socorro, A., Zhang, Y., Li, S., Sarver, B. A. J., et al. (2023). Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00684-7

Vancouver

He KY, Khramtsova EA, Cabrera-Socorro A, Zhang Y, Li S, Sarver BAJ, et al. Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants. Molecular Neurodegeneration. 2023. doi:10.1186/s13024-023-00684-7. PMID: 38017580.

BibTeX

@article{he2023-38017580,
  author  = {He, K. Y. and Khramtsova, E. A. and Cabrera-Socorro, A. and Zhang, Y. and Li, S. and Sarver, B. A. J. and Smets, B. and Li, Q. S. and De Muynck, L. and Parrado, A. R. and Lovestone, S. and Black, M. H.},
  title   = {{Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants}},
  journal = {Molecular Neurodegeneration},
  year    = {2023},
  doi     = {10.1186/s13024-023-00684-7},
  pmid    = {38017580},
  url     = {https://doi.org/10.1186/s13024-023-00684-7}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 12 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

Among 455,306 UK Biobank participants, 37 carried one copy of the APOE Christchurch variant and none had developed Alzheimer's or mild cognitive impairment by the data freeze. The sample was too small to directly test dementia risk, so this cannot establish that the variant protects against Alzheimer's.

Study details

Limitations

No homozygotes were found, so the original Colombian finding could not be validated; too few carriers overlapped with imaging, metabolomics or proteomics data for analysis; only baseline measurements were used; statin adjustment relied on self-report at baseline and may be incomplete.

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 50 of the 98 points it could be judged on, which is 51 of 100. Total 51 of 100.50 of the 98 points we could judge = 51 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 50 of the 98 points we could judge it on, which is 51 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Molecular Neurodegeneration)
Journal's citation record 2 / 4 Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 4 / 4 455,306 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 8 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.6 citations a year over 5 year(s) since 2023
Impact for its field and year 2 / 6 Cited 1.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Mary Helen Black: h-index 45 (OpenAlex, whole career)
Institution's track record 0 / 3 Janssen Research & Development (United States): institution h-index 416 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38017580)
Free to read — / 2 Access not recorded — left out of this score
Points 50 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 50 of the 98 points we could judge it on is 51 out of 100.
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Genetics from nearby years

Also in Genetics

198 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.

Similar studies

More on Genetics

See all studies in Genetics →